These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8566445)

  • 1. Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape.
    Toes RE; Feltkamp MC; Ressing ME; Vierboom MP; Blom RJ; Brandt RM; Hartman M; Offringa R; Melief CJ; Kast WM
    Biochem Soc Trans; 1995 Aug; 23(3):692-6. PubMed ID: 8566445
    [No Abstract]   [Full Text] [Related]  

  • 2. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors.
    Macedo MF; Velders MP; Nieland JD; Rudolf MP; Weijzen S; Da Silva DM; Franke A; Holt G; Loviscek K; Carbone M; Kast WM
    Monaldi Arch Chest Dis; 1998 Apr; 53(2):211-8. PubMed ID: 9689811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
    Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
    Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
    Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
    Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
    Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
    J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
    Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.
    Chen CH; Ji H; Suh KW; Choti MA; Pardoll DM; Wu TC
    Gene Ther; 1999 Dec; 6(12):1972-81. PubMed ID: 10637448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
    Herd KA; Harvey T; Khromykh AA; Tindle RW
    Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16.
    Sarkar AK; Tortolero-Luna G; Nehete PN; Arlinghaus RB; Mitchell MF; Sastry KJ
    Viral Immunol; 1995; 8(3):165-74. PubMed ID: 8833270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
    Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
    Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.